Genomic & Biopharma NewsThree signs of real progress against sickle cell disease
A decade ago, the United Nations declared June 19 to be World Sickle Cell Awareness Day- and for good reason.
|News Medical Life Sciences, 2019-06-19 14:45:40|
Gilead taps Nurix's protein degradation tech in $45M cancer pact
Gilead is enlisting Nurix to create new cancer medicines that break down disease-causing proteins. The Big Pharma is handing over $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.
|Fierce Biotech, 2019-06-19 14:36:35|
Researchers identify genes linked with survival in children with biliary atresia
Scientists at Cincinnati Children's Hospital Medical Center have identified an expression pattern of 14 genes at the time of diagnosis that predicts two year, transplant-free survival in children with biliary atresia – the most common diagnosis leading to liver transplants in children.
|News Medical Life Sciences, 2019-06-19 14:31:54|
Bio-Techne nets FDA breakthrough ticket in prostate cancer liquid biopsy
Bio-Techne’s urine test, designed to track down the exosomes and genomic markers released from prostate cancer cells, has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.
|Fierce Biotech, 2019-06-19 14:16:04|
Men who eat yogurt twice a week are less likely to develop bowel cancer
Eating two or more servings of yogurt (over 245g) per week can reduce the risk of men developing pre-cancerous growths that can lead to bowel cancer.
|News Medical Life Sciences, 2019-06-19 14:15:00|
Kymera rolls out new animal data on its lead protein-degradation drug to treat lymphoma
Kymera is presenting new preclinical data on the lead protein-degradation drug in its pipeline, KYM-001, which it’s developing to treat a particularly aggressive subset of B-cell lymphoma. In mice, the drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.
|Fierce Biotech, 2019-06-19 14:06:40|
Revolutionary cancer drugs that target any tumor to be fast-tracked into hospitals by NHS
Patients in England could be some of the first in the world to be treated with revolutionary cancer drugs that can target any type of tumor.
|News Medical Life Sciences, 2019-06-19 13:51:00|
Yale researchers offer insight into the hunger hormone
In a new study, Yale researchers offer insight into leptin, a hormone that plays a key role in appetite, overeating, and obesity. Their findings advance knowledge about leptin and weight gain, and also suggest a potential strategy for developing future weight-loss treatments, they said.
|News Medical Life Sciences, 2019-06-19 13:42:34|
ORB Employees Participate in 2019 Martin Luther King Day Event
ORB employees get a rare break from the lab on January 21, 2019. A group of Ocean Ridge Biosciences employees stepped out of the lab on a beautiful South Florida winter day to take part in an event honoring Martin Luther King. We got our hands dirty planting some flowers and shrubs at a local park in Deerfield Beach.
|ORB Company News, 2019-01-22 23:24:59|
Harnessing the microbiome potential
Spring is underway in parts of the US, and while Florida by no means undergoes the dramatic reappearance of foliage or colorful clumps of daffodils and azaleas, the southern part of the sunshine state experiences its share of spring renewals. For instance, recently a brood of Muscovy duck (Cairina moschata) hatchlings appeared near Ocean Ridge Biosciences' laboratory.
|ORB Company Blog, 2017-03-31 21:41:45|
Allergan, following years of turmoil and resistance, heads for split: analyst
Allergan's share prices have significantly fallen from their high in 2015, but now the company is ready to make a big move in response to its struggles, one analyst writes.
|Fierce Pharma, 2019-06-19 13:27:25|